{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:34:00Z","timestamp":1769045640543,"version":"3.49.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.japh.2021.04.010","type":"journal-article","created":{"date-parts":[[2021,4,21]],"date-time":"2021-04-21T06:56:41Z","timestamp":1618988201000},"page":"e126-e131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screening for metabolic disorders through pharmacy collaborative practice agreement"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3836-9375","authenticated-orcid":false,"given":"Jonathan G.","family":"Leung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1090-9635","authenticated-orcid":false,"given":"Amanda","family":"Owen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3425-7181","authenticated-orcid":false,"given":"Andrew J.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5897-4869","authenticated-orcid":false,"given":"Emily K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2012-7140","authenticated-orcid":false,"given":"Melinda","family":"Dively-White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kreps","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9875-6126","authenticated-orcid":false,"given":"Kendra K.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathryn M.","family":"Schak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2021.04.010_bib1","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S2215-0366(19)30416-X","article-title":"Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis","volume":"7","author":"Pillinger","year":"2020","journal-title":"Lancet Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.japh.2021.04.010_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.06.008","article-title":"Life expectancy among persons with schizophrenia or bipolar affective disorder","volume":"131","author":"Laursen","year":"2011","journal-title":"Schizophr Res"},{"issue":"6","key":"10.1016\/j.japh.2021.04.010_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1192\/bjp.bp.109.076950","article-title":"Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis","volume":"198","author":"Mitchell","year":"2011","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib4","first-page":"596","article-title":"American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes","volume":"27","year":"2004","journal-title":"Diabetes Care. Consens dev conference on antipsychotic drugs and obesity and diabetes"},{"issue":"9","key":"10.1016\/j.japh.2021.04.010_bib8","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1176\/appi.ajp.2020.177901","article-title":"The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia","volume":"177","author":"Keepers","year":"2020","journal-title":"Am J Psychiatry"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib9","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1177\/1060028017731421","article-title":"Monitoring of recommended metabolic laboratory parameters among Medicaid recipients on second-generation antipsychotics in federally qualified health centers","volume":"52","author":"Uzal","year":"2018","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.japh.2021.04.010_bib10","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/schbul\/sbm038","article-title":"UK Prescribing Observatory for Mental Health. A UK audit of screening for the metabolic side effects of antipsychotics in community patients","volume":"33","author":"Barnes","year":"2007","journal-title":"Schizophr Bull"},{"issue":"10","key":"10.1016\/j.japh.2021.04.010_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-007633","article-title":"Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK","volume":"5","author":"Barnes","year":"2015","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.japh.2021.04.010_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1600-0447.2008.01203.x","article-title":"Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme","volume":"118","author":"Barnes TR Paton","year":"2008","journal-title":"Acta Psychiatr Scand"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib13","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1078390320906196","article-title":"Improved prescriber adherence to guidelines on antipsychotic medication management through increased access to metabolic monitoring forms","volume":"27","author":"Bomboy","year":"2021","journal-title":"J\u00a0Am Psychiatr Nurses Assoc"},{"issue":"10","key":"10.1016\/j.japh.2021.04.010_bib14","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/cap.2017.0034","article-title":"Improving cardiometabolic monitoring of children on antipsychotics","volume":"27","author":"Cotes","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.japh.2021.04.010_bib15","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1177\/1078390317752444","article-title":"Improving adherence to atypical antipsychotic agent screening guidelines in pediatric patients: a quality improvement project within an integrated community mental health setting","volume":"24","author":"Featherston","year":"2018","journal-title":"J\u00a0Am Psychiatr Nurses Assoc"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/bmjoq-2017-000223","article-title":"Initiative to improve the cardiogenic safety of antipsychotic medication in community mental health patients","volume":"6","author":"Parks","year":"2017","journal-title":"BMJ Open Qual"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10597-016-0007-5","article-title":"A\u00a0randomized controlled trial of a patient-centered approach to improve screening for the metabolic side effects of antipsychotic medications","volume":"53","author":"Kreyenbuhl","year":"2017","journal-title":"Community Ment Health J"},{"issue":"1","key":"10.1016\/j.japh.2021.04.010_bib18","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1176\/ps.62.1.pss6201_0012","article-title":"Best practices: Implementation of a glucose screening program based on diffusion of innovation theory methods","volume":"62","author":"Nicol","year":"2011","journal-title":"Psychiatr Serv"},{"issue":"6","key":"10.1016\/j.japh.2021.04.010_bib19","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.apnu.2016.03.004","article-title":"Improving metabolic syndrome screening on patients on second generation antipsychotic Medication","volume":"30","author":"Kioko","year":"2016","journal-title":"Arch Psychiatr Nurs"},{"issue":"5","key":"10.1016\/j.japh.2021.04.010_bib20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/JCP.0000000000000931","article-title":"Can we improve physical health monitoring for patients taking antipsychotics on a mental health inpatient unit?","volume":"38","author":"Ross","year":"2018","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.japh.2021.04.010_bib21","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2710.2012.01369.x","article-title":"Evaluation of a computer-based intervention to enhance metabolic monitoring in psychiatry inpatients treated with second-generation antipsychotics","volume":"37","author":"DelMonte","year":"2012","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"2","key":"10.1016\/j.japh.2021.04.010_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jcpt.12368","article-title":"Persistence of metabolic monitoring for psychiatry inpatients treated with second-generation antipsychotics utilizing a computer-based intervention","volume":"41","author":"Lee","year":"2016","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"5","key":"10.1016\/j.japh.2021.04.010_bib23","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/jamia\/ocx115","article-title":"Medication-related clinical decision support alert overrides in inpatients","volume":"25","author":"Nanji","year":"2018","journal-title":"J\u00a0Am Med Inform Assoc"},{"key":"10.1016\/j.japh.2021.04.010_bib24","doi-asserted-by":"crossref","DOI":"10.1093\/fampra\/17.suppl_1.S11","article-title":"Experimental and quasi-experimental designs for evaluating guideline implementation strategies","volume":"17","author":"Grimshaw","year":"2000","journal-title":"Fam Pract"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319121001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:49:39Z","timestamp":1761544179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319121001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S1544319121001655"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2021.04.010","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of Inpatient Psychiatric Facility Quality Reporting program measure: Screening for metabolic disorders through pharmacy collaborative practice agreement","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2021.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}